-
公开(公告)号:US11447753B2
公开(公告)日:2022-09-20
申请号:US16868243
申请日:2020-05-06
申请人: Northwestern University , Board of Regents of the University of Nebraska , Trustees of Tufts College (AKA Tufts University)
IPC分类号: A61K39/245 , A61K39/25 , C12N7/00 , C07K14/005 , A61K39/12 , A61K35/763 , A61K39/00
摘要: Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.
-
公开(公告)号:US11241450B2
公开(公告)日:2022-02-08
申请号:US16849946
申请日:2020-04-15
申请人: TUFTS UNIVERSITY
发明人: Philip G. Haydon , Jinbo Lee
IPC分类号: A61K31/7072 , A61K31/7052 , A61K31/706 , A61K31/7068 , A61K31/7064 , A61K31/7042 , C07D405/14 , C07D413/14 , C07D405/04 , C07H19/067 , C07F9/6558 , C07F9/6574 , C07F9/09 , C07F9/22 , C07H19/06 , A61K9/00
摘要: This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.
-
公开(公告)号:US10912862B2
公开(公告)日:2021-02-09
申请号:US14377128
申请日:2013-02-05
IPC分类号: A61L27/58 , A61L27/22 , A61L27/36 , B29C39/00 , A61L27/54 , A61L27/56 , A61L27/38 , B29L31/00
摘要: The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.
-
公开(公告)号:US20200263147A1
公开(公告)日:2020-08-20
申请号:US16868246
申请日:2020-05-06
申请人: Northwestern University , Board of Regents of the University of Nebraska , Trustees of Tufts College (AKA Tufts University)
IPC分类号: C12N7/00 , A61K35/763 , C07K14/005 , A61K39/25 , A61K39/245 , A61K39/12
摘要: Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.
-
公开(公告)号:US10544183B2
公开(公告)日:2020-01-28
申请号:US14775426
申请日:2014-03-13
申请人: TUFTS UNIVERSITY , Philip G. Haydon , Jinbo Lee
发明人: Philip G. Haydon , Jinbo Lee
IPC分类号: A61K31/7064 , A61K31/7068 , A61K31/7072 , C07H19/06
摘要: This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.
-
公开(公告)号:US20190048364A1
公开(公告)日:2019-02-14
申请号:US16159185
申请日:2018-10-12
申请人: Tufts University
发明人: Thomas J. Diefenbach
摘要: Methods, tip assemblies and kits are provided for introducing material into cells. The tip assemblies include an attachment portion, a channel portion, and a constriction that function to reduce fluid pressure as a fluid passes through the constriction portion from the channel portion, whereby the tip assemblies form pores in the membranes of cells and introduce material into the cells. The material includes for example one selected from the group of: an inorganic compound, a drug, a genetic material, a protein, a carbohydrate, a synthetic polymer, and a pharmaceutical composition.
-
公开(公告)号:US10202441B2
公开(公告)日:2019-02-12
申请号:US15191739
申请日:2016-06-24
申请人: TUFTS UNIVERSITY
发明人: Charles B. Shoemaker
摘要: Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes a disease agent that is a toxin, for example a Clostridium difficile toxin, a Shiga toxin, a ricin toxin, or an anthrax toxin.
-
公开(公告)号:US20190009274A1
公开(公告)日:2019-01-10
申请号:US15752547
申请日:2016-08-12
摘要: Described herein are microfluidic devices and systems for high density cell culture and/or high throughput cell assays. Methods of using the same are also provided herein. In some embodiments, the microfluidic devices and systems described herein provide rapid and automated trapping of single embryos in ordered arrays.
-
公开(公告)号:US10131127B2
公开(公告)日:2018-11-20
申请号:US14408091
申请日:2013-06-14
申请人: Tufts University
发明人: Chris Mutzel , Sameer Sonkusale
摘要: A method of making an electrically active structure includes applying a backplane onto a substrate, applying a paint layer onto said backplane, applying a stencil layer on said paint layer, patterning an electrically active structure onto said paint layer through said stencil layer, and removing said stencil layer.
-
公开(公告)号:US09913855B2
公开(公告)日:2018-03-13
申请号:US14432104
申请日:2013-09-27
申请人: TUFTS UNIVERSITY
发明人: Philip G. Haydon , Jinbo Lee
IPC分类号: A61K31/7072 , A61K31/7052 , A61K31/706 , A61K31/7068 , A61K31/7064 , A61K31/7042 , C07D405/14 , C07D413/14 , C07D405/04 , C07H19/067 , C07F9/09 , C07F9/22 , C07F9/6558 , C07F9/6574 , C07H19/06 , A61K9/00
CPC分类号: A61K31/7072 , A61K9/0019 , A61K31/7042 , A61K31/7052 , A61K31/706 , A61K31/7064 , A61K31/7068 , C07D405/04 , C07D405/14 , C07D413/14 , C07F9/09 , C07F9/22 , C07F9/65586 , C07F9/65742 , C07F9/65744 , C07H19/06 , C07H19/067
摘要: This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.
-
-
-
-
-
-
-
-
-